Publications
697
Citations
28,128
Est. group size
~20
Recurring co-author estimate
Active years
53
Publishing since 1974
Raphael E. Pollock's research focuses on sarcoma, a group of cancers arising in bone, fat, muscle, and connective tissue, with particular attention to liposarcoma (a fat-tissue cancer) and related soft-tissue tumors. His work investigates the molecular signaling pathways (such as Notch and STAT1) and metabolic changes that drive tumor growth, spread, and treatment resistance, alongside studies on surgical and combination-therapy approaches for rare sarcoma subtypes.
Publication output was relatively steady (8-16 per year) from 2017-2022 before sharply spiking in 2023, likely reflecting a burst of related supplementary and companion outputs, then declining toward more typical levels in 2024-2026.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Notch signaling regulates the secretion of pro-metastatic factors in extracellular vesicles in liposarcoma
Cancer Letters · 2026
- EE314 A Cost-Utility Analysis in Patients With Inflammatory Bowel Disease and Iron Deficiency Anemia in the Netherlands: Reduced Hypophosphatemia and Fracture Incidence With Ferric Derisomaltose Versus Ferric Carboxymaltose
Value in Health · 2024
- VERTICAL MICRO-NANOCHANNEL INTEGRATION FOR RELATIVE SURFACE PROTEIN ABUNDANCE QUANTIFICATION ON LIPOSARCOMA EXTRACELLULAR VESICLES
2024
- Notch signaling regulates a metabolic switch through inhibiting PGC-1α and mitochondrial biogenesis in dedifferentiated liposarcoma
Oncogene · 2023
- Supplementary Figure 1 from Unphosphorylated STAT1 Promotes Sarcoma Development through Repressing Expression of Fas and Bad and Conferring Apoptotic Resistance
2023
- Supplementary Table 2 from Unphosphorylated STAT1 Promotes Sarcoma Development through Repressing Expression of Fas and Bad and Conferring Apoptotic Resistance
2023
- Data from Unphosphorylated STAT1 Promotes Sarcoma Development through Repressing Expression of Fas and Bad and Conferring Apoptotic Resistance
2023
- Supplementary Figure 1 Legend from Unphosphorylated STAT1 Promotes Sarcoma Development through Repressing Expression of Fas and Bad and Conferring Apoptotic Resistance
2023
- Supplementary Figure 1 Legend from Unphosphorylated STAT1 Promotes Sarcoma Development through Repressing Expression of Fas and Bad and Conferring Apoptotic Resistance
2023
- Data from Unphosphorylated STAT1 Promotes Sarcoma Development through Repressing Expression of Fas and Bad and Conferring Apoptotic Resistance
2023
- Supplementary Figure 1 from Unphosphorylated STAT1 Promotes Sarcoma Development through Repressing Expression of Fas and Bad and Conferring Apoptotic Resistance
2023
- Supplementary Table 1 from Unphosphorylated STAT1 Promotes Sarcoma Development through Repressing Expression of Fas and Bad and Conferring Apoptotic Resistance
2023
- Supplementary Table 1 from Unphosphorylated STAT1 Promotes Sarcoma Development through Repressing Expression of Fas and Bad and Conferring Apoptotic Resistance
2023
- Supplementary Table 2 from Unphosphorylated STAT1 Promotes Sarcoma Development through Repressing Expression of Fas and Bad and Conferring Apoptotic Resistance
2023
- Supplementary Methods, Tables 1-2, Figures 1-3 from MiR-155 Is a Liposarcoma Oncogene That Targets Casein Kinase-1α and Enhances β-Catenin Signaling
2023
- Cancer Research×19
- Journal of Surgical Oncology×9
- Annals of Surgical Oncology×8
- Holland‐Frei Cancer Medicine×4
- Annals of Surgery×3
- Valerie P. Grignol
Medicine · The Ohio State University
- Ashley Patton
Medicine · The Ohio State University
- Fernanda Costas Casal de Faria
Medicine · The Ohio State University
- Paul E. Wakely
Medicine · The Ohio State University
- David A. Liebner
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile